McKesson Hits New 12-Month High

Shares of the healthcare distribution company reach record levels amid strong financial performance.

Published on Feb. 26, 2026

Got story updates? Submit your updates here. ›

McKesson Corporation (NYSE:MCK), a leading healthcare services and distribution company, saw its share price reach a new 52-week high of $971.93 during trading on Thursday. The stock closed at $965.38, up 1.0% on the day, with trading volume of 48,585 shares. The company's strong financial results and positive analyst sentiment have driven the stock to these record levels.

Why it matters

McKesson's new 12-month high reflects the company's solid financial footing and growth prospects within the healthcare distribution industry. As a major supplier of pharmaceuticals, medical-surgical products, and technology solutions, McKesson's performance is seen as an indicator of broader trends in the healthcare sector.

The details

Several Wall Street analysts have recently issued positive reports on McKesson, with UBS Group raising its price target to $980 and maintaining a "buy" rating. Zacks Research, however, downgraded the stock to "hold" from "strong buy." Overall, 13 analysts rate McKesson as a "buy," while 4 have a "hold" recommendation, according to data from MarketBeat.com.

  • McKesson's share price reached a new 52-week high of $971.93 during mid-day trading on Thursday, February 26, 2026.
  • The stock closed at $965.38 on February 26, 2026, up 1.0% for the day.

The players

McKesson Corporation

A global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products, and health care technology solutions.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

McKesson's new 12-month high underscores the company's strong position in the healthcare distribution market, driven by its diversified product offerings and positive analyst sentiment. As a key player in the industry, McKesson's performance is seen as a bellwether for the broader healthcare sector.